دورية أكاديمية
Brain tumor response to nimotuzumab treatment evaluated on magnetic resonance imaging.
| العنوان: | Brain tumor response to nimotuzumab treatment evaluated on magnetic resonance imaging. |
|---|---|
| المؤلفون: | Dalmau ER; Images Group, Center of Genetic Engineering and Biotechnology, La Habana, Cuba., Cabal Mirabal C, Martínez GS, Dávila AL, Suárez JC, Cabanas Armada R, Rodriguez Cruz G, Darias Zayas D, Castillo MR, Valle Garrido L, Sotolongo LQ, Fernández MM |
| المصدر: | Pediatrics international : official journal of the Japan Pediatric Society [Pediatr Int] 2014 Feb; Vol. 56 (1), pp. 43-6. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Blackwell Science Asia Country of Publication: Australia NLM ID: 100886002 Publication Model: Print Cited Medium: Internet ISSN: 1442-200X (Electronic) Linking ISSN: 13288067 NLM ISO Abbreviation: Pediatr Int Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Carlton South, Vic. : Blackwell Science Asia, c1999- |
| مواضيع طبية MeSH: | Antibodies, Monoclonal, Humanized/*administration & dosage , Brain/*pathology , Brain Neoplasms/*drug therapy , Magnetic Resonance Imaging/*methods, Adolescent ; Brain Neoplasms/diagnosis ; Child ; Child, Preschool ; Disease Progression ; Dose-Response Relationship, Drug ; Female ; Follow-Up Studies ; Humans ; Male ; Reproducibility of Results ; Treatment Outcome |
| مستخلص: | Background: Nimotuzumab, a humanized monoclonal antibody anti-epidermal growth factor receptor, has been shown to improve survival and quality of life in patients with pediatric malignant brain tumor. It is necessary, however, to increase the objective response criteria to define the optimal therapeutic schedule. The aim of this study was to obtain magnetic resonance imaging (MRI) and magnetic resonance spectroscopy (MRS) quantitative information related to dimensions and morphology, molecular mobility and metabolic activity of the lesion and surroundings in order to evaluate any changes through time. Methods: Fourteen pediatric patients treated with nimotuzumab were evaluated on MRI and MRS for >2 years. Each patient was their own control. The MRI/MRS pulse sequence parameters were standardized to ensure experimental reproducibility. Results: A total of 71.4% of patients had stable disease; 21.4% had objective response and 7.1% had progression of disease during the >2 year evaluation period. Conclusions: MRI/MRS data with clinical information provide a clearer picture of treatment response and confirm once again that nimotuzumab is effective in the treatment of pediatric brain tumor. These imaging procedures can be a useful tool for the clinical evaluation of study protocol in clinical practice. (© 2013 The Authors. Pediatrics International © 2013 Japan Pediatric Society.) |
| فهرسة مساهمة: | Keywords: brain tumor; magnetic resonance imaging; nimotuzumab |
| المشرفين على المادة: | 0 (Antibodies, Monoclonal, Humanized) 6NS400BXKH (nimotuzumab) |
| تواريخ الأحداث: | Date Created: 20130906 Date Completed: 20150413 Latest Revision: 20171116 |
| رمز التحديث: | 20240628 |
| DOI: | 10.1111/ped.12212 |
| PMID: | 24003867 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1442-200X |
|---|---|
| DOI: | 10.1111/ped.12212 |